Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics Reports Second Quarter 2015 Financial Results

GlobeNewswire August 10, 2015

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire August 4, 2015

Cara Therapeutics to Announce Second Quarter 2015 Financial Results on August 10, 2015

GlobeNewswire August 3, 2015

Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire July 29, 2015

Cara Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire July 27, 2015

Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus

GlobeNewswire July 23, 2015

Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus

GlobeNewswire July 23, 2015

Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics' CR845

PR Newswire July 14, 2015

Cara Therapeutics Completes Enrollment of Phase 2 Trial of I.V. CR845 in Uremic Pruritus

GlobeNewswire June 23, 2015

Why Are Cannabis Labs Important and What Makes Them a Great Investment?

Accesswire June 22, 2015

Cara Therapeutics to Sponsor Symposium and Present Poster at the College on Problems of Drug Dependence 77th Annual Meeting

GlobeNewswire June 10, 2015

Cara Therapeutics to Present at the 2015 International Conference on Opioids

GlobeNewswire June 5, 2015

Retail Layoffs Highlight Opportunity in the Cannabis Space

Accesswire May 19, 2015

Cara Therapeutics Reports First Quarter 2015 Financial Results

GlobeNewswire May 12, 2015

Cara Therapeutics to Present at American Pain Society 34th Annual Scientific Meeting

GlobeNewswire May 6, 2015

Cara Therapeutics to Announce First Quarter 2015 Financial Results on May 12, 2015

GlobeNewswire May 5, 2015

Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids

GlobeNewswire April 15, 2015

Peak Pharma Prepares for Human Marketplace as Veterinary Segment Propels Early Commercial Success

Accesswire April 14, 2015

Cara Therapeutics to Webcast Presentation at 14th Annual Needham Healthcare Conference

GlobeNewswire April 7, 2015

Cara Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

GlobeNewswire March 26, 2015